| 产品描述: | JZP-361是一种有效的、可逆的、选择性的人重组 MAGL (hMAGL) 抑制剂,IC50 为 46 nM。JZP-361 还具有抗组胺能活性,可用于哮喘的研究。 |
| 靶点: |
hMAGL:46 nM (IC50);hABHD6:1.79 μM (IC50);hFAAH:7.24 μM (IC50) |
| 体外研究: |
JZP-361 has almost 150-fold higher selectivity over human recombinant fatty acid amide hydrolase (hFAAH, IC50 = 7.24 μM) and 35-fold higher selectivity over human α/β-hydrolase-6 (hABHD6, IC50 = 1.79 μM). JZP-361 retains H1 antagonistic affinity (pA2 = 6.81) but did not show cannabinoid receptor activity, when tested at concentrations ≤10 μM. JZP-361 displays favorable interactions within the active site of hMAGL including the important hydrogen-bonding of the carbonyl oxygen to the oxyanion hole. |
| 参考文献: |
1. Jayendra Z Patel, et al. Loratadine analogues as MAGL inhibitors. Bioorg Med Chem Lett. 2015 Apr 1;25(7):1436-42. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.464 ml |
12.319 ml |
24.638 ml |
| 5 mM |
0.493 ml |
2.464 ml |
4.928 ml |
| 10 mM |
0.246 ml |
1.232 ml |
2.464 ml |
| 50 mM |
0.049 ml |
0.246 ml |
0.493 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |